Thermo Fisher Points to Improving End-Market Activity

Thermo Fisher Scientific Inc. (NYSE: TMO ) on Thursday reported second-quarter adjusted earnings of $6.03 per share, beating the street view of $5.71.

The life science giant’s quarterly sales of $11.994 billion increased 10% year-over-year, beating the analyst consensus estimate of $11.701 billion.

Organic revenue growth was 5%.

Customer Activity Improves Across End Markets In an earnings conference call, the company noted good customer activity continues to strengthen across end markets during the second quarter.

Life Sciences Solutions sales increased 12.6% to $2.815 billion.

Analytical Instruments sales were up 6.9% at $1.847 billion.

Read Also: Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy Specialty Diagnostics revenues reached $1.205 billion (+6.3%), and Laboratory Products and Biopharma Services sales were up 11.6% to $6.693 billion.

Pharma, Academic And Industrial Businesses Drive Growth Within pharma and biotech, Thermo Fisher delivered mid-single-digit growth in the second quarter, led by bioproduction and clinical research businesses, as well as the Research and Safety Market channel.

The academic and government segment grew low single digits in the second quarter, driven by the chromatography and mass spectrometry business.

The industrial and applied segment delivered mid-single-digit growth.

Thermo Fisher Raises 2026 Guidance "It’s great to see customer activity continue to strengthen across our end markets," said Marc Casper, Chairman and CEO. "Our recently closed acquisitions are performing very well, and at the halfway point in the year we’re well positioned to deliver a great 2026." Thermo Fisher Scientific raised its fiscal 2026 adjusted earnings per share guidance from $24.64-$25.12 to $24.93-$25.33 versus the consensus of $24.86.

The company increased its annual sales guidance from $47.3 billion-$48.1 billion to $47.40 billion-$48.10 billion compared to the consensus of $47.767 billion.

Thermo Fisher says expectations for 2026 revenue growth have increased to about 4%.

It added that the guidance range remains 3%-4%, and now expects to deliver at the upper end of that range. "We continue to have an active pipeline of M&A opportunities in our highly fragmented industry," Casper further added.

TMO Price Action: Thermo Fisher Scientific shares were up 9.05% at $574.09 at the time of publication on Thursday, according to Pro data.

Read Also: Sam Altman, OpenAI Sued After ChatGPT Allegedly Told Florida Man to Stay Home Before a 'Massive' Blood Clot Nearly Killed Him Photo: Shutterstock